Company: IONQ
Filing Date: 2025-10-10
Form Type: 424B5
Source: 0001193125-25-236452
Chunk: 1

Company: IonQ, Inc.
Filing Date: 2025-10-10
Form: 424B5
Chunk 1
---
” on page 8 of the accompanying prospectus and “Description of Warrants” on page S-13of this prospectus supplement and page 20 of the accompanying prospectus for a more complete description of the securities offered hereby. Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “IONQ.” We do not intend to list the Warrants on any exchange. On October 9, 2025, the last reported sale price of our common stock on the NYSE was $77.50 per share.

|                                  |     | Per share(1)(2) |        |     | Per           
 Pre-funded    
 Warrant(2)(3) |         |     | Total |                    |
|:---------------------------------|:----|:----------------|-------:|:----|:--------------|--------:|:----|:------|-------------------:|
| Public offering price            |     | $               |  93.00 |     | $             | 92.9999 |     | $     | 2,000,001,699.4600 |
| Underwriting discounts(4)        |     | $               | 0.9300 |     | $             |  0.9300 |     | $     |    20,000,022.0000 |
| Proceeds, before expenses, to us |     | $               |  92.07 |     | $             | 92.0699 |     | $     | 1,980,001,677.4600 |

| (1) | The above proceeds do not include shares of common stock that may be issued upon the exercise of the Warrants. |

| (2) | The public offering price per share and per Pre-funded Warrant each includes a nominal amount of consideration 
 allocated to each accompanying Series B Warrant.                                                               |

| (3) | Each Pre-funded Warrant and accompanying two Series B Warrants is being sold together at a combined offering                                           
 price of $93.00 (with a nominal exercise price of $0.0001 per share remaining unpaid as of the issuance date with respect to each Pre-funded Warrant). |

| (4) | No underwriting compensation is payable in connection with the Series B Warrants. See                       
 “Underwriting” for a description of all underwriting compensation payable in connection with this offering. |

Investing in our common stock involves risks. See “ Risk Factors” beginning on